In the first three quarters, UNI MEDICAL's profit attributable to common shareholders increased by approximately 4.2% year-on-year

According to the announcement from UNI MEDICAL (02666), the overall operation of the group remained stable and improved in the first three quarters of 2025, with positive results achieved in various key areas. As of September 30, 2025, the group's revenue increased by approximately 12.8% compared to the same period last year, while profit for the period rose by about 7.6% year-on-year, and profit attributable to ordinary shareholders increased by approximately 4.2%.

In terms of comprehensive medical services, the group actively responded to the impacts of medical insurance payment reforms, stricter fund supervision, and centralized procurement of drugs and consumables. The group enhanced its medical service capabilities, focusing on refined management of specialties and diseases, exploring standardized diagnosis and treatment for diseases, and driving quality and efficiency improvements in its operations. The overall operational status of the group's medical institutions was good in the first three quarters of 2025: through the implementation of non-stop outpatient services, extended hours, specialist clinics, and specialty outpatient services, the number of outpatient and emergency visits increased against the trend, with a year-on-year growth of approximately 3.4%; relying on lean management principles, the group continuously optimized the diagnosis and treatment service processes, with total discharges increasing by about 1.7% compared to the same period last year, and the average length of stay decreasing to 9.1 days, leading to continuous improvement in operational efficiency; by establishing scientific, effective, reasonable, and unified disease pathways, the proportion of medical service revenue reached 36.5%, an increase of 2.3 percentage points year-on-year, significantly optimizing the business structure; and strengthening cost control, focusing on the management of drugs and consumables, conducting special actions, with the cost of drug consumption as a percentage of revenue decreasing from 44.9% to 43.0%, effectively enhancing the medical institutions' risk resistance and sustainable development capabilities.

In the areas of specialized medical services and health technology, the group adhered to a "dual-wheel drive" of connotative development and extensive expansion around core medical resources, cultivating distinctive businesses and core capabilities, and striving to create a second growth curve. Currently, this sector has made progress in layout expansion and capability building, with relevant merger and acquisition projects also advancing smoothly.

In terms of financial services, the group adhered to its functional positioning of serving the real economy and the development of its main business, solidly promoting the transformation and innovation of its financial services. While steadily upgrading traditional businesses, it accelerated its transformation in four directions: medical health, equipment manufacturing, chemical medicine, and innovative businesses, and pioneered a new model of "financing leasing + full lifecycle management" for medical equipment, utilizing industrial resources to promote the development of elderly care finance and digital finance. As of September 30, 2025, the total interest-earning assets of the group remained stable compared to the beginning of 2025, with net interest margin and net profit margin steadily improving, overall asset quality remaining stable and controllable, and provision coverage maintained prudently